Iryna Drozd
Corvus Pharmaceuticals (NASDAQ:CRVS) has received FDA Orphan Drug Designation for its drug candidate soquelitinib for the treatment of T-cell lymphoma.
The company expects to begin a Phase 3 registrational study for the product in patients with relapsed peripheral T-cell lymphoma in Q2.
The designation provides certain benefits to drug developers, including seven years market exclusivity if the drug is approved.